Covid drug and vac­cine sales nose­dive, dent­ing bio­phar­ma rev­enue across the board

Mod­er­na re­port­ed a steep de­cline in Covid-19 vac­cine sales in the first quar­ter that mim­ic­ked a plunge in rev­enue re­port­ed by oth­er man­u­fac­tur­ers of Covid vac­cines and treat­ments.

Many of the pan­dem­ic play­ers in­clud­ing Pfiz­er, Mer­ck and Mod­er­na have warned that Covid drug and vac­cine sales would de­cline this year, es­pe­cial­ly when com­par­ing the first three months of 2023 to the same quar­ter a year ago, when there was a resur­gence in Covid cas­es due to new vari­ants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER